Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Beam Therapeutics (Nasdaq: BEAM) has appointed Sravan K. Emany as Chief Financial Officer, effective December 19, 2024. Emany joins from Ironwood Pharmaceuticals, where he served as CFO and COO. His extensive background includes leadership roles at Integra LifeSciences as Corporate VP of Commercial Excellence and Chief Strategy Officer, and nearly a decade in investment banking at Bank of America, where he led healthcare sector M&A as Managing Director.
CEO John Evans highlighted Emany's exceptional background in capital formation and allocation strategy, noting his importance in guiding Beam through its next growth phase as the company advances multiple clinical programs in hematology and genetic disease. Emany expressed enthusiasm about joining Beam's mission to transform genetic disease treatment through precision medicines.
Beam Therapeutics (Nasdaq: BEAM) ha nominato Sravan K. Emany come Direttore Finanziario, con effetto dal 19 dicembre 2024. Emany proviene da Ironwood Pharmaceuticals, dove ha ricoperto il ruolo di CFO e COO. Il suo ampio background include ruoli di leadership presso Integra LifeSciences come VP Corporate dell'Eccellenza Commerciale e Chief Strategy Officer, e quasi un decennio nel settore bancario di investimento presso Bank of America, dove ha guidato le operazioni di M&A nel settore sanitario come Managing Director.
Il CEO John Evans ha sottolineato l'eccezionale esperienza di Emany nella formazione di capitale e nella strategia di allocazione, evidenziando il suo ruolo cruciale nel guidare Beam attraverso la sua prossima fase di crescita mentre l'azienda avanza in diversi programmi clinici in ematologia e malattie genetiche. Emany ha espresso entusiasmo per unirsi alla missione di Beam di trasformare il trattamento delle malattie genetiche attraverso i farmaci di precisione.
Beam Therapeutics (Nasdaq: BEAM) ha nombrado a Sravan K. Emany como Director Financiero, con efecto a partir del 19 de diciembre de 2024. Emany llega de Ironwood Pharmaceuticals, donde se desempeñó como CFO y COO. Su amplia trayectoria incluye puestos de liderazgo en Integra LifeSciences como VP Corporativo de Excelencia Comercial y Director de Estrategia, además de casi una década en banca de inversión en Bank of America, donde lideró fusiones y adquisiciones en el sector de la salud como Director General.
El CEO John Evans destacó la excepcional trayectoria de Emany en la formación de capital y la estrategia de asignación, señalando su importancia para guiar a Beam en su próxima fase de crecimiento mientras la empresa avanza en múltiples programas clínicos en hematología y enfermedades genéticas. Emany expresó su entusiasmo por unirse a la misión de Beam de transformar el tratamiento de las enfermedades genéticas a través de medicamentos de precisión.
Beam Therapeutics (Nasdaq: BEAM)는 Sravan K. Emany를 2024년 12월 19일부터 CFO로 임명했습니다. Emany는 Ironwood Pharmaceuticals에서 CFO 및 COO로 재직했습니다. 그의 광범위한 경력에는 Integra LifeSciences에서 상무이사 및 Chief Strategy Officer로서의 리더십 역할이 포함되어 있으며, Bank of America에서 거의 10년 동안 헬스케어 부문의 M&A를 관리하는 담당 이사로 재직했습니다.
CEO John Evans는 Emany의 자본 형성 및 배분 전략에 대한 탁월한 경력을 강조하며, 회사가 혈액학 및 유전 질환에서 여러 임상 프로그램을 진행하는 동안 Beam을 다음 성장 단계로 이끄는 데 그의 중요성을 언급했습니다. Emany는 정밀 의약품을 통해 유전 질환 치료를 변혁하려는 Beam의 사명에 합류하게 되어 기쁘다고 밝혔습니다.
Beam Therapeutics (Nasdaq: BEAM) a nommé Sravan K. Emany au poste de Directeur Financier, à compter du 19 décembre 2024. Emany vient d'Ironwood Pharmaceuticals, où il était CFO et COO. Son vaste parcours comprend des postes de direction chez Integra LifeSciences en tant que VP Corporatif de l'Excellence Commerciale et Chief Strategy Officer, ainsi que près de dix ans dans la banque d'investissement à Bank of America, où il a dirigé des fusions et acquisitions dans le secteur de la santé en tant que Directeur Général.
Le CEO John Evans a souligné l'expérience exceptionnelle d'Emany en matière de formation de capital et de stratégie d'allocation, notant son importance pour guider Beam dans sa prochaine phase de croissance alors que l'entreprise avance dans plusieurs programmes cliniques en hématologie et maladies génétiques. Emany a exprimé son enthousiasme à rejoindre la mission de Beam visant à transformer le traitement des maladies génétiques grâce à des médicaments de précision.
Beam Therapeutics (Nasdaq: BEAM) hat Sravan K. Emany zum Chief Financial Officer ernannt, der ab dem 19. Dezember 2024 tätig wird. Emany kommt von Ironwood Pharmaceuticals, wo er als CFO und COO tätig war. Sein umfangreicher Hintergrund umfasst Führungspositionen bei Integra LifeSciences als Corporate VP für Commercial Excellence und Chief Strategy Officer sowie nahezu ein Jahrzehnt im Investment Banking bei der Bank of America, wo er als Managing Director im Bereich M&A im Gesundheitssektor tätig war.
CEO John Evans hob Emanys außergewöhnlichen Hintergrund in der Kapitalbildung und Allokationsstrategie hervor und betonte seine Bedeutung, Beam durch die nächste Wachstumsphase zu führen, während das Unternehmen mehrere klinische Programme in der Hämatologie und genetischen Erkrankungen vorantreibt. Emany äußerte seine Begeisterung, Teil von Beams Mission zu werden, die Behandlung genetischer Erkrankungen durch Präzisionsmedikamente zu transformieren.
- Appointment of experienced CFO with strong healthcare and financial markets background
- Strategic addition to leadership team during clinical pipeline advancement phase
- New CFO brings valuable M&A and capital markets expertise
- None.
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc.
"Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital formation and allocation strategy going forward," said John Evans, chief executive officer of Beam. "With his deep understanding of value creation in the life sciences, along with significant operational and financial experience, Sravan is uniquely positioned to help guide Beam through its next phase of growth as we advance multiple clinical programs across our hematology and genetic disease portfolio. We are excited to welcome him to the team as we continue to build on our momentum and work to create lasting impact for patients.”
"Beam’s mission to transform the treatment of genetic diseases with precision medicines is both inspiring and urgent. I am honored to join a company at the forefront of scientific innovation, especially as it advances a robust clinical pipeline with the potential to make a profound difference in patients’ lives,” said Mr. Emany. “With a strong financial foundation and a period of significant opportunity ahead, Beam is poised to drive meaningful progress in its pioneering clinical pipeline and differentiated base editing platform. I look forward to contributing to the company’s success and helping ensure we have the resources to deliver life-changing therapies to patients worldwide.”
Prior to joining Ironwood, Mr. Emany served as corporate vice president, commercial excellence and chief strategy officer of Integra LifeSciences Holdings Corporation, a publicly held global healthcare company, and as vice president of strategy, treasury and investor relations before that. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities, formerly Bank of America Merrill Lynch, for nearly a decade, culminating in his service as managing director in the mergers and acquisitions group, where he led numerous mergers and acquisitions in the healthcare sector. He also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany serves on the board of directors of Assertio Holdings, Inc. (Nasdaq: ASRT). He holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the timing and effective date of the appointment of Mr. Emany; the contributions Mr. Emany may make in his role with the company; the therapeutic applications and potential of our technology, including with respect to ESCAPE; our plans to advance our programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When will Sravan Emany start as CFO at Beam Therapeutics (BEAM)?
What was Sravan Emany's previous role before joining Beam Therapeutics (BEAM)?
What is Beam Therapeutics (BEAM) main focus area?
